Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

More than 1 in 4 adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the ...

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

Attorney General Ken Paxton filed a lawsuit this week against Eli Lilly for allegedly bribing Texas health care providers to ...

GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide mimic naturally occurring hormones that regulate blood sugar, appetite, and digestion. GLP-1 (glucagon-like ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Texas is intervening in the litigation as a plaintiff with the Health Choice Alliance, a research organization jointly represented by The Lanier Law Firm and McKool Smith PC.

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's ...

By Nqobile Dludla and Siyanda Mthethwa JOHANNESBURG (Reuters) -Danish drugmaker Novo Nordisk introduced its weight-loss drug ...